Cancer Treatment Today

Oxaliplatin induced neuropathy can be difficult to manage. Two recent phase II studies suggested that Cymbalta(duloxetine) is effective for oxapliplatin induced neuropathy. Both studies were in small number of patients and there was a significant monority of patients who did not tolerate treatment. Overall benefit was modest. Both studies concluded that using this drug is feasible. This was followed by an abstract at 2012 ASCO meeting of a phase

Buprenorphin comes in a formulation that can be taken via  patch thorugh the skin or under the tongue. In October 2002, the Food and Drug Administration (FDA) approved buprenorphine monotherapy product, Subutex®, and a buprenorphine/naloxone combination product, Suboxone®, for use in narcotic addiction treatment. IT saturates narcotic receptors and prevents a “high”. The combination product is designed to decrease the potential for abuse by

Buprenorphin comes in a sublingual and transdermal formulation. In October 2002, the Food and Drug Administration (FDA) approved buprenorphine monotherapy product, Subutex®, and a buprenorphine/naloxone combination product, Suboxone®, for use in opioid addiction treatment. The combination product is designed to decrease the potential for abuse by injection. The transdermal form is well-established for treatment of chronic cancer pain and. It was

Buprenorphin comes in a sublingual and transdermal formulation. In October 2002, the Food and Drug Administration (FDA) approved buprenorphine monotherapy product, Subutex®, and a buprenorphine/naloxone combination product, Suboxone®, for use in opioid addiction treatment. The combination product is designed to decrease the potential for abuse by injection. The transdermal form is well-established for treatment of chronic cancer pain and. It was